Filing Flows › Comparisons › HROW vs VNDA
Harrow vs Vanda Pharmaceuticals: HROW and VNDA compared
Harrow is the larger company: $70.7M of revenue in its latest quarter (Q2 2026) against $69.8M for Vanda Pharmaceuticals (Q3 2026). Vanda Pharmaceuticals is growing faster (+24% against +11% a year earlier). Harrow is more profitable, with an operating margin of -15.6% against -33.7%.
Where the money goes: HROW and VNDA
Harrow (HROW) · Q2 2026
Harrow, Q2 2026: revenue $70.7M (+11% year over year), operating margin -15.6%, net loss $17.3M, operating cash flow −$9.8M. The chart follows the revenue to costs, profit and cash.
Vanda Pharmaceuticals (VNDA) · Q3 2026
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
| Harrow (HROW) | Vanda Pharmaceuticals (VNDA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $70.7M | $69.8M |
| Revenue growth, Y/Y | +11% | +24% |
| Operating margin | -15.6% | -33.7% |
| Net earnings | −$17.3M | −$22.6M |
| Net margin | -24.4% | -32.3% |
| Operating cash flow | −$9.8M | −$28.4M |
Where the revenue comes from
Harrow
- Product sales, net: $70.6M (100%)
- Other revenues: $90K (0%)
Vanda Pharmaceuticals
- Fanapt®: $38.8M (56%)
- HETLIOZ® net product sales: $21.7M (31%)
- PONVORY® net product sales: $7.7M (11%)
- NEREUSTM: $1.6M (2%)
Questions
Which is bigger, Harrow or Vanda Pharmaceuticals?
Harrow is the larger company: $70.7M of revenue in its latest quarter (Q2 2026) against $69.8M for Vanda Pharmaceuticals (Q3 2026).
Is Harrow or Vanda Pharmaceuticals growing faster?
Vanda Pharmaceuticals is growing faster (+24% against +11% a year earlier).
Which is more profitable, Harrow or Vanda Pharmaceuticals?
Harrow is more profitable, with an operating margin of -15.6% against -33.7%.
More: Harrow earnings · how Harrow makes money · Vanda Pharmaceuticals earnings · how Vanda Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.